227 related articles for article (PubMed ID: 34958982)
1. Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma.
Pavord ID; Hanania NA; Corren J
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):410-419. PubMed ID: 34958982
[TBL] [Abstract][Full Text] [Related]
2. Controversies in Allergy: Are Biologic Treatment Responses in Severe Asthma the Same in Adults and Children?
Gaberino CL; Bacharier LB; Jackson DJ
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2673-2682. PubMed ID: 37517797
[TBL] [Abstract][Full Text] [Related]
3. Use of biologics for the treatment of moderate-to-severe asthma: the age of personalized medicine.
Mustafa SS; Patrawala S; Khurana S
Curr Opin Pulm Med; 2022 May; 28(3):266-273. PubMed ID: 35131991
[TBL] [Abstract][Full Text] [Related]
4. Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma.
Chan R; RuiWen Kuo C; Lipworth B
J Allergy Clin Immunol Pract; 2020; 8(10):3363-3370. PubMed ID: 32673880
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.
Bourdin A; Brusselle G; Couillard S; Fajt ML; Heaney LG; Israel E; McDowell PJ; Menzies-Gow A; Martin N; Mitchell PD; Petousi N; Quirce S; Schleich F; Pavord ID
J Allergy Clin Immunol Pract; 2024 Apr; 12(4):809-823. PubMed ID: 38280454
[TBL] [Abstract][Full Text] [Related]
6. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion.
Buhl R; Bel E; Bourdin A; Dávila I; Douglass JA; FitzGerald JM; Jackson DJ; Lugogo NL; Matucci A; Pavord ID; Wechsler ME; Kraft M
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):422-432. PubMed ID: 34763123
[TBL] [Abstract][Full Text] [Related]
7. How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit.
Pepper AN; Hanania NA; Humbert M; Casale TB
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1081-1088. PubMed ID: 33685606
[TBL] [Abstract][Full Text] [Related]
8. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
Trevor J; Lugogo N; Carr W; Moore WC; Soong W; Panettieri RA; Desai P; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):579-587.e1. PubMed ID: 34273485
[TBL] [Abstract][Full Text] [Related]
9. Biologics in the treatment of asthma in children and adolescents.
Bacharier LB; Jackson DJ
J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649
[TBL] [Abstract][Full Text] [Related]
10. Emerging care management strategies for severe asthma: integrating biologic therapy.
Spjut R
Am J Manag Care; 2022 Sep; 28(11 Suppl):S203-S209. PubMed ID: 36648385
[TBL] [Abstract][Full Text] [Related]
11. Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials.
Chen W; Reddel HK; FitzGerald JM; Beasley R; Janson C; Sadatsafavi M
Respir Res; 2023 May; 24(1):120. PubMed ID: 37131185
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils).
Petsky HL; Cates CJ; Lasserson TJ; Li AM; Turner C; Kynaston JA; Chang AB
Thorax; 2012 Mar; 67(3):199-208. PubMed ID: 20937641
[TBL] [Abstract][Full Text] [Related]
13. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
[TBL] [Abstract][Full Text] [Related]
14. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.
Kyriakopoulos C; Gogali A; Markozannes G; Kostikas K
Eur Respir Rev; 2024 Apr; 33(172):. PubMed ID: 38657997
[TBL] [Abstract][Full Text] [Related]
15. Biologics in severe asthma: the overlap endotype - opportunities and challenges.
Bakakos A; Loukides S; Usmani OS; Bakakos P
Expert Opin Biol Ther; 2020 Dec; 20(12):1427-1434. PubMed ID: 32779950
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.
Arron JR; Choy DF; Scheerens H; Matthews JG
Ann Am Thorac Soc; 2013 Dec; 10 Suppl():S206-13. PubMed ID: 24313774
[TBL] [Abstract][Full Text] [Related]
17. Biological treatments for severe asthma: A major advance in asthma care.
Busse WW
Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
[TBL] [Abstract][Full Text] [Related]
18. Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma.
Kurokawa M; Koya T; Takeuchi H; Hayashi M; Sakagami T; Ishioka K; Gon Y; Hasegawa T; Kikuchi T
J Asthma; 2020 Jan; 57(1):71-78. PubMed ID: 30489179
[No Abstract] [Full Text] [Related]
19. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.
Pavord ID; Holliday M; Reddel HK; Braithwaite I; Ebmeier S; Hancox RJ; Harrison T; Houghton C; Oldfield K; Papi A; Williams M; Weatherall M; Beasley R;
Lancet Respir Med; 2020 Jul; 8(7):671-680. PubMed ID: 32171064
[TBL] [Abstract][Full Text] [Related]
20. Role of Biologics in Asthma.
McGregor MC; Krings JG; Nair P; Castro M
Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
